相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Therapeutic Oligonucleotides Targeting Liver Disease: TTR Amyloidosis
Christoph Niemietz et al.
MOLECULES (2015)
Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis
Harry R. Bueller et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Targeting APOC3 in the Familial Chylomicronemia Syndrome
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Changes in Mipomersen Dosing Regimen Provide Similar Exposure With Improved Tolerability in Randomized Placebo-Controlled Study of Healthy Volunteers
JoAnn D. Flaim et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2014)
Clinical pharmacokinetics of second generation antisense oligonucleotides
Rosie Z. Yu et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial
John L. Berk et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)
Safety and Efficacy of RNAi Therapy for Transthyretin Amyloidosis
Teresa Coelho et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Tafamidis for transthyretin familial amyloid polyneuropathy A randomized, controlled trial
Teresa Coelho et al.
NEUROLOGY (2012)
Allele Specific Expression of the Transthyretin Gene in Swedish Patients with Hereditary Transthyretin Amyloidosis (ATTR V30M) Is Similar between the Two Alleles
Nina Norgren et al.
PLOS ONE (2012)
Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment
Merrill D. Benson et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2010)
RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
C. Frank Bennett et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2010)
A possible role for miRNA silencing in disease phenotype variation in Swedish transthyretin V30M carriers
Malin Olsson et al.
BMC MEDICAL GENETICS (2010)
Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2′-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN
Richard S. Geary et al.
BIOCHEMICAL PHARMACOLOGY (2009)
Transthyretin: the servant of many masters
Joel N. Buxbaum et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2009)
Antisense oligonucleotide pharmacokinetics and metabolism
Richard S. Geary
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2009)
Transthyretin: More than meets the eye
Carolina Estima Fleming et al.
PROGRESS IN NEUROBIOLOGY (2009)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides
MD Benson et al.
MUSCLE & NERVE (2006)
Lack of pharmacokinetic interaction for ISIS 113715, a 2 '-0-methoxyethyl modified antisense oligonucleotide targeting protein tyrosine phosphatase 1B messenger RNA, with oral antidiabetic compounds metformin, glipizide or rosiglitazone
Richard S. Geary et al.
CLINICAL PHARMACOKINETICS (2006)
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture
N Reixach et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Tabulation of human transthyretin (TTR) variants, 2003
LH Connors et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2003)
Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy
HJ Lachmann et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents - A comparative analysis
TA Vickers et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α
KL Sewell et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
分享论文
